Proton beam therapy

Marija Popović-Vuković1, Jelena Bokun1,2, Dragana Stanić1,2, Borko Nidžović1, Marina Nikitović1,2

1Institute of Oncology and Radiology of Serbia, Belgrade, Serbia;
2University of Belgrade, Faculty of Medicine, Belgrade, Serbia

Received: January 12, 2021
Revised: September 22, 2021
Accepted: October 1, 2021
Online First: October 11, 2021
DOI: https://doi.org/10.2298/SARH210112081P

Accepted papers are articles in press that have gone through due peer review process and have been accepted for publication by the Editorial Board of the Serbian Archives of Medicine. They have not yet been copy-edited and/or formatted in the publication house style, and the text may be changed before the final publication.

Although accepted papers do not yet have all the accompanying bibliographic details available, they can already be cited using the year of online publication and the DOI, as follows: the author’s last name and initial of the first name, article title, journal title, online first publication month and year, and the DOI; e.g.: Petrović P, Jovanović J. The title of the article. Srp Arh Celok Lek. Online First, February 2017.

When the final article is assigned to volumes/issues of the journal, the Article in Press version will be removed and the final version will appear in the associated published volumes/issues of the journal. The date the article was made available online first will be carried over.

*Correspondence to:
Marija POPOVIĆ-VUKOVIĆ
Institute of Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia
E-mail: marija.popovic@ncrc.ac.rs
Proton beam therapy

Protonска терапија

SUMMARY
Proton beam therapy (PBT) is an advanced type of radiotherapy that shows a dosimetric advantage over photon beam therapy and provides superior dose distribution. PBT may improve patient survival by improving the local disease control while reducing toxicity to normal organs, which may result in fewer treatment related complications. During the last decade technological progress opened up new possibilities in the planning and conducting PBT, so indications were gradually expanded to different cancers. However, many biological aspects of PBT are still unclear, and its role in clinical settings is controversial. Proton therapy is considered to be safe and effective for different types of pediatric cancers, and that it is suitable in treatment of ocular melanomas, chordomas and chondrosarcomas. Future research and more prospective clinical studies with long term follow up are required in order to clearly determine the benefits and proper indications for PBT.

Keywords: proton therapy; radiotherapy; cancer

Интродукция

Proton beam therapy (PBT) is a modern radiotherapy (RT) technique that uses protons. In 1946, Wilson first proposed PBT for medical use considering the advantages of proton RT compared with conventional photon RT. This suggestion was based on the known physical property of protons, which is that they slow down during penetration of tissue [1, 2].

The first PBT patient series was published in 1958, by researchers at the Lawrence-Berkeley National Laboratory, where initially patients with radio-resistant tumors such as chordoma and melanoma were treated. Technological progress opened up new possibilities in the planning and conducting PBT, so indications were gradually expanded to other cancers. The expenses of PBT is much higher compared to conventional photon RT due to the high cost of proton beam technology and maintenance. First proton center was established in 1990.
California, and today there are about 70 proton therapy centers worldwide with more than 190,000 patients treated with PBT [3, 4].

Increasingly more evidence has been showed for the advantages of PBT in clinical use, but it is not good for every tumor type and site. Also, some biological aspects of PBT are still unclear. It is necessary to understand the advantages and limitations of protons [5].

**Physical and biological aspects of PBT**

Protons are heavy charged particles which continuously slow down during penetration of matter as they slow down in a function of depth. Energy loss continues until the entire energy of proton is depleted after which they come to an abrupt stop, which results in a steep and localized peak of dose. This process of dose deposition produces a characteristic depth-dose curve, Bragg curve. The point of highest energy loss of proton is called the Bragg peak (Figure 1). The depth of the peak depends of the initial energy of proton and the deposited dose beyond the range is minimal. PBT dose distribution is superior to the dose distribution of conventional photon RT, but it is still debatable whether the dosimetric advantages of PBT translates to clinically relevant decreases in toxicity. Different randomized clinical trials which compare protons and photons are currently ongoing [2,6].

The proton dose is defined as Gray (Gy), which is calculated by multiplying the physical dose by the relative biological effectiveness (RBE). For photon and electron external beam RT the RBE is considered to be 1. Proton radiotherapy is planned assuming that the proton RBE relative to photons is 1.1. However, experimental evidence showed that proton RBE isn’t constant and that it changes along the treatment field. According to in vitro studies, the highest RBE is found at the distal edge and in the distal fall-off region within the Bragg curve. Still, there remain several uncertainties in understanding variations in biological response after proton irradiation compared to photon irradiation. Current experiments on the response of normal and tumor tissue to proton therapy should be continued [7].
Proton therapy for different cancers

The heavier subatomic particles deliver their energy more precisely to the tumor area comparing to photons. The justification for the clinical use of proton therapy is the possibility for dose escalation to the tumor which leads to better local disease control probability. This is possible due to better sparing of surrounding healthy tissue compared to other radiotherapy techniques. Due to the reduced treatment volume and a lower integral dose, patient tolerance is increased with lower morbidity rate. PBT may improve the survival rate with significant reduction of treatment related complications, which results in preserving the quality of life of treated patients.

As other highly conformal photon therapy techniques, PBT is indicated for tumors located close to serial organs, where a small radiation overdose can lead to severe complications. Irregular shaped lesions close to critical structures are suitable for proton radiotherapy treatment [3,8].

Pediatric cancers

Radiation therapy plays an important role as part of multimodal treatment for many pediatric malignancies, especially for brain tumors, sarcomas, lymphomas and neuroblastoma. Treating children with radiotherapy is a great challenge because they have higher radiation sensitivity and lower radiation tolerance than adults, and late toxicity of radiotherapy is an issue for long term survivors. Reduction in quality of life due to growth and development retardation, as well as secondary malignancies remain a significant problem for treated children. It is neccessary to provide effective radiation therapy with the least possible morbidity. The physical characteristics of protons are promising in terms of achieving significant clinical benefits [9, 10].

Dosimetric comparation studies between photons and protons in treatment of medulloblastoma, ependymoma, Ewing sarcoma, rhabdomyosarcoma showed the superiority
of PTB over photons in reducing dose to surrounding healthy organs and tissues (Figure 2). Clinical results are limited, but the first evidence confirmed similar survival rates with fewer treatment related side effects for PBT, which could have positive impact on the quality of life of treated children [11].

Gross et al. reported favorable neurocognitive outcomes in pediatric patients with brain tumors with the use of PBT compared with photon RT, according to findings from a study that included 125 patients [13].

Kahaley et al. published first longitudinal study comparing intellectual outcomes between pediatric patients treated for medulloblastoma with PBT and photon radiotherapy, and showed that PBT was associated with superior intellectual outcomes [14].

On the other hand, Kralik et al. pointed out that pediatric patients with brain tumors treated with PBT have a high incidence of radiation necrosis, frequently distant from the tumor area. Multiple chemotherapy agents were a significant risk factor associated with radiation necrosis [15].

Bhattacharya et al. done retrospective imaging review of 46 patients with brain tumors who were treated by PBT. Large vessel progressive cerebral arteriopathy was described in 25% of patients which is more than in previously reported studies. This study also pointed out the appearance of white matter changes remote to the region of irradiation in two patients.

There is a need for continued close follow up of children treated with PBT, which will enable us to better understand long-term effects, safety and benefits of this therapy [16].

**Ocular tumors**

Ocular melanomas represent perfect model for a malignant tumor requiring high dose radiotherapy with complex dose distribution within the target volume, and PBT is recognized
to be one of the main radiotherapy treatment options, as well as for other ocular tumors. [17] (Figure 3).

PBT for ocular melanoma results in excellent local control of disease with preserved quality of life of treated patients. Van Beek et al. published a retrospective study of 306 patients with uveal melanoma. Half of patients were treated with PBT and the other half with fractionated stereotactic photon beam radiotherapy (fSRT). The 5-year local tumour control rates were 96.1% for both groups. However, vitreous haemorrhage was significantly less common after PBT than fSRT [19].

PBT is also a new option for conservative treatment of conjunctival squamous cell carcinoma (SCC). Milazzotto et al. reported a retrospective analysis of 15 patients with conjunctival SCC treated with PBT who had gross residual disease after surgery or were not candidates for surgery. Overall survival (OS) and disease-free survival (DFS) rates were 86.6% respectively, after a median follow-up of 48 months. Treatment was well tolerated, without significant acute or late toxicity [20].

**Chordoma of the skull base and spine**

Chordoma of the skull base is challenging to treat due to tumor location, proximity to critical neural and vascular structures and tumor radioresistance. Gross total resection of these tumors is often not possible, so adjuvant radiation therapy is an important treatment modality which can improve local disease control and overall survival. High dose photon based radiotherapy can be used, but usually can’t achieve therapeutic dosage because of the proximity to dose-limiting structures: optic nerve, chiasm, brain stem, spinal cord and brain [21].

Application of proton therapy with simultaneous integrated boost for these malignancies made possible to deliver radical doses to target volumes while minimizing toxicity for organs at risk. This treatment approach affords excellent local disease control while sparing normal surrounding structures [22].
Treatment of spinal and sacral chordoma represents great challenge because of the proximity of the spinal cord and nerve roots. Radiation tolerance of the spinal cord is considered at 48-54 Gy, much below necessary doses adequate for local control for these tumors. Chordoma require high radiation doses of 60-70 Gy. PBT offers dose escalation for treatment of tumors in this location, but the current clinical evidence is still limited and further research is needed [23].

**Reirradiation**

Tumor recurrence is in most cases unresectable because of many different factors. The possibility of reirradiation is limited by the previously applied radiotherapy treatment, dose constrains for surrounding critical organs, and the time period passed since the previous radiation treatment. The high conformality and rapid fall-off of radiation dose at the distal end of the target offer significant possibility for reirradiation with protons. By sparing adjacent normal tissues, proton therapy can more safely apply definitive instead of palliative doses of reirradiation [3, 24].

Saeed at al. published series of 45 patients with recurrent glioblastoma multiforme treated with proton reirradiation between 2012-2018. The median interval between initial diagnosis and disease recurrence was 20 months. In this series 40 patients completed full reirradiation course to a median dose of 46.2 Gy. The median progression free survival (PFS) was 13,9 months with median OS 14,2 months. One grade 3 acute toxicity was observed, 3 patients developed grade 3 late toxicity, and no grade 4 or 5 toxicities were reported [25].

Although small number of published studies on reirradiation with PBT have shown promising results, adequate patient selection is required for the careful use of proton reirradiation.
Other tumors

The application of PBT has been used for the treatment of different malignancies which include CNS, head and neck tumors, prostate, breast, liver, esophageal and lung cancer. However, the role of PBT in clinical settings is still controversial, and there are certain technical challenges in planning and delivery for different treatment sites [5].

CONCLUSION

PBT is an advanced type of radiotherapy that achieves a dose distribution which is generally superior to photon beam therapy. This may allow dose escalation to the tumor target volume, better sparing of surrounding tissues, thus potentially improving local disease control and survival while at the same time reducing toxicity and improving quality of life of treated patients. Still, a question remains as to whether dosimetric advantages of PBT leads to clinically relevant decreases in toxicity. Clinical evidence supporting wide use of protons is mixed despite its high potential. Promising results have been reported for many types of cancers, however they are based on small studies. There are still uncertainties about the radiobiology of protons that can have an impact on the molecular and cellular effects of PBT. Further research and prospective clinical studies with extensive follow up of treated patients are needed in order to determine effectiveness and safety of PBT.

Conflict of interest: None declared.
REFERENCES

1. Tian X, Liu K, Hou Y, Cheng J, Zhang J. The evolution of proton beam therapy: Current and future status (Review). Mol Clin Oncol. 2018;8(1):15-21. doi: 10.3892/mco.2017.1499. PMID: 29399346.
2. Paganiotti H, Beltran C, Both A, Dong L, Flanz J, Furutani K et al. Roadmap: proton therapy physics and biology. Phys. Med. Biol. 2021;66(5): doi: 10.1088/1361-6560/abcd16. PMID: 33227715.
3. Yuan T, Zhan Z, Qian C. New frontiers in proton therapy: applications in cancers. Cancer Commun. 2019;39:61. doi: 10.1186/s40808-019-0407-3. PMID: 31640788.
4. Lawrence JH, Tobias CA, Born JL, McCombs RK, Roberts JE, Anger HO et al. Pituitary irradiation with high-energy proton beams: A preliminary report. Cancer Res 1958;18(2):121-134. PMID: 13511365.
5. Hu M, Jiang L, Cui X, Zhang J, Yu J. Proton beam therapy for cancer in the era of precision medicine. J Hematol Oncol. 2018;11(1):136. doi: 10.1186/s13045-018-0683-4. PMID: 30541578.
6. Mohan R, Grosshans D. Proton Therapy – Present and Future. Adv Drug Deliv Rev. 2017;109:26-44. doi: 10.1016/j.addr.2016.11.006. PMID: 27919760.
7. Ilicic K, Combs S, Schmid T. New insights in the relative radiobiological effectiveness of proton irradiation. Radiat Oncol. 2018;13(1):6. doi: 10.1186/s13014-018-0954-9. PMID: 29338744.
8. Byun H, Han M, Yang K, Kim J, Yoo G, Koom W et al. Physical and Biological Characteristics of Particle Therapy for Oncologists. Cancer Res Treat. 2021;53(3):611-620. doi: 10.4143/crt.2021.066. PMID: 34139805.
9. Merchant T, Kortmann R. Pediatric Radiation Therapy, first edition 2018; Springer International Publishing. ISBN 978-3-319-4345-9.
10. Steinmeier T, Schleithoff S, Timmermann B. Evolving radiotherapy techniques in paediatric oncology. Clinical Oncology 2019;31(3):142-150. doi: 10.1016/clon.2018.12.005 PMID: 30639254.
11. Thomas H, Timmermann B. Paediatric proton therapy. The British journal of radiology, 2020;93(1170). doi:10.1016/j.bjr.2016.11.006. PMID: 27919760.

4. PMID: 30997512.
12. Tsang D, Patel S. Proton beam therapy for cancer. CMAJ 2019;191(24):E664-666. doi: 10.1503/cmaj.190008.
13. Gross J, Powell S, Zelko F, Hartsell W, Goldman A, Fangusaro J et al. Neuropsychological outcomes of pediatric brain tumor patients treated with proton or X-ray radiation therapy. Int J Radiat Oncol Biol Phys. 2018;102(3):S52. doi: 10.1016/j.ijrobp.2018.06.045. PMID: 30997512.
14. Kahalley LS, Peterson R, Ris MD, Janzen L, Okcu MF, Grosshans DR et al. Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma. J Clin Oncol 2020 Feb 10;38(5):450-461. doi: 10.1200/JCO.19.01706. PMID: 31774710.
15. Kralik S, Ho C, Finke W, Buchsbaum J, Haskins C, Shih C. Radiation Necrosis in Pediatric Patients with Brain Tumors Treated with Proton Radiotherapy. American Journal of Neuroradiology. 2015;36(8):1572-1578. doi: 10.3174/ajnr.A4333. PMID: 26138138.
16. Bhattacharya D, Chhabda S, Lakshmanan R, Tan R, Warne R, Benenati M et al. Spectrum of neuroimaging findings post-proton beam therapy in a large pediatric cohort. Childs Nerv Syst. 2021;37:435-446 doi: 10.1007/s00381-020-04819-9. PMID: 32705327.
17. Reichstein A, Brock A. Radiation therapy for uveal melanoma: a review of treatment methods available in 2021. Current Opinion in Ophthalmology. 2021;32(3):183-190. doi: 10.1097/ICU.0000000000000761. PMID: 33770014.
18. SCCA Proton Therapy, Ocular melanoma treatment. Available from: https://www.sccaprotontherapy.com/cancers-treated/ocular-melanoma-treatment
19. Van Beek, Ramdas W, Angi M, Van Rij C, Naus N, Kacperek A et al. Local tumour control and radiation side effects for fractionated stereotactic proton beam radiotherapy compared to proton beam radiotherapy in uveal melanoma. Radiother Oncol. 2021;157:219-224. doi: 10.1016/j.radonc.2021.01.030. PMID: 33549643.
20. Milazzotto R, Liardo R, Privitera G, Raffaele L, Salamone V, Arena F et al. Proton beam radiotherapy of locally advanced or recurrent conjunctival squamous cell carcinoma: experience of the CATANA Centre. Journal of Radiotherapy in Practice 2020;p:1-8. doi: 10.1017/S1460396920000953.
21. Guan X, Gao J, Hu J, Hu W, Yang J, Qiu X et al. The preliminary results of proton and carbon ion therapy for chordoma and chondrosarcoma of the skull base and cervical spine. Radiat Oncol. 2019;14:205. doi:10.1186/s13014-019-1407-9. PMID: 31752953.
22. Parzen JS, Li X, Zheng W, Ding X, Kabolizadeh P. Proton Therapy for Skull-Base Chordomas and Chondrosarcomas: Initial Results From the Beaumont Proton Therapy Center. Cureus. 2021;13(5):e15278. doi: 10.7759/cureus.15278. PMID: 34194880.
23. Pennington Z, Ehresman J, Elsamadicy A, Shin J, C Goodwin, Schwab J et al. Systematic review of charged-particle therapy for chordomas and sarcomas of the mobile spine and sacrum. Neurosurg Focus 2021;50 (5):E17. doi: 10.3171/2021.2.FOCUS201059.
24. Simone C, Plastaras J, Jabbour S, Lee A, Lee N, Choi I et al. Proton Reirradiation: Expert Recommendations for Reducing Toxicities and Offering New Chances of Cure in Patients With Challenging Recurrence Malignancies. Seminars in Rad Oncol. 2020;30(3):253-261. doi: 10.1016/j.semradonc.2020.02.007. PMID: 32503791.
25. Saeed AM, Khairnar R, Sharma AM, Larson GL, Tsai HK, Wang CJ, et al. Clinical Outcomes in Patients with Recurrent Glioblastoma Treated with Proton Beam Therapy Reirradiation: Analysis of the Multi-Institutional Proton Collaborative Group Registry. Adv Radiat Oncol. 2020 Apr 22;5(5):978-983. doi: 10.1016/j.adro.2020.03.022. PMID: 33083661.
Figure 1. The diagram of dose distributions for photon, single proton beam and spread-out proton beam [5]
Figure 2. Dose distributions for photon (left) and proton (right) craniospinal radiotherapy plan [12]
Figure 3. Isodose distributions for proton (left) and photon (right) treatment plans for ocular melanoma [18]